Citius Pharmaceuticals to Present at Upcoming October Investor Conferences
Citius Pharmaceuticals to Present at Upcoming October Investor Conferences
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will present at two investor conferences during the month of October 2021.
花旗制药公司(Citius PharmPharmticals，Inc.)(以下称“Citius”或“公司”)(纳斯达克股票代码：CTXR)是一家晚期生物制药公司，致力于一流重症监护产品的开发和商业化，重点是肿瘤学、附属癌症护理中的抗感染产品、独特的处方药产品和干细胞疗法。该公司今天宣布，将在2021年10月的两个投资者大会上发言。
EVENT: Benzinga Rising Stars: Catalytic Small Cap Growth Conference DATE: Thursday, October 7, 2021 Citius Executive Chairman Leonard Mazur will present at 9:05 a.m. ET. His presentation will be available for viewing on Benzinga's live stream channel.
活动：本辛加后起之秀：催化小盘股增长大会日期：2021年10月7日(星期四)花旗执行主席伦纳德·马祖尔(Leonard Mazur)将于上午9：05出席。Et.他的演讲将在Benzinga的直播频道上观看。
EVENT: Dawson James Securities 6th Annual Small Cap Growth Conference DATE: Thursday, October 21, 2021 Citius Executive Chairman Leonard Mazur will present at 8:55 a.m. ET in Track 1 and will be available for 1-on-1 meetings with registered conference attendees. The conference will be held October 20-21 at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Florida. A webcast of the presentation will be available on the Events page of the Citius Investors website.
事件：道森·詹姆斯证券公司(Dawson James Securities)第六届年度小盘股增长大会日期：2021年10月21日(星期四)花旗执行主席伦纳德·马祖尔(Leonard Mazur)将于上午8点55分出席。ET在轨道1中，将可用于与已注册的与会者进行一对一会议。会议将于10月20日至21日在佛罗里达州朱庇特市海滨广场的温德姆大木星酒店举行。演示文稿的网络直播将在Citius Investors网站的活动页面上进行。
At the conferences, Mr. Mazur will discuss the Company's growing pipeline of therapies targeting unmet medical needs consisting of two late-stage assets completing Phase 3 trials, three potential first-and-only prescription treatments in their indications, and a next-generation stem cell therapy program.
在会议上，马祖尔先生将讨论该公司针对未得到满足的医疗需求的日益增长的治疗流水线，其中包括完成第三阶段试验的两项晚期资产、三种潜在的第一种也是唯一一种适应症处方药，以及下一代干细胞治疗计划。
About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok(R), an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed enrollment in its Pivotal Phase 3 trial. Mino-Lok(R) was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute respiratory distress syndrome (ARDS) associated with COVID-19. For more information, please visit www.citiuspharma.com.
Citius制药公司简介Citius是一家晚期生物制药公司，致力于一流危重护理产品的开发和商业化，重点是肿瘤学、辅助癌症护理中的抗感染药物、独特的处方药和干细胞疗法。该公司有两个后期候选产品：Mino-Lok(R)和I/Ontak(E7777)。Mino-Lok(R)是一种用于治疗导管相关血流感染(CRBSI)患者的抗生素锁定解决方案，目前正在招募患者参加第三阶段关键优势试验；I/Ontak(E7777)是一种用于皮肤T细胞淋巴瘤(CTCL)初步适应症的新型IL-2R免疫疗法，它已经完成了其关键第三阶段试验的登记。Mino-Lok(R)获得美国食品和药物管理局(FDA)的快速通道称号。I/Ontak已获得FDA指定的治疗CTCL和外周T细胞淋巴瘤(PTCL)的孤儿药物。通过其子公司NoveCite公司，花旗公司正在开发一种从诱导多能干细胞中提取的治疗急性呼吸疾病的新型专利间充质干细胞疗法，近期的重点是治疗与新冠肺炎有关的急性呼吸窘迫综合征。欲了解更多信息，请访问www.citiuspharma.com。
Investor Relations for Citius Pharmaceuticals: Ilanit Allen Vice President, Investor Relations and Corporate Communications T: 908-967-6677 x113 E: ir@citiuspharma.com
投资者关系和公司通联部副总裁伊兰尼特·艾伦(Ilanit Allen)电话：908-967-6677 x113电子邮件：ir@citiuspharma.com
https://mma.prnewswire.com/media/1593817/Citius_Logo.jpg
Https://mma.prnewswire.com/media/1593817/Citius_Logo.jpg
https://c212.net/c/img/favicon.png?sn=NE31297&sd=2021-10-06
Https://c212.net/c/img/favicon.png?sn=NE31297&sd=2021-10-06
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-upcoming-october-investor-conferences-301394276.html
查看原创内容以下载multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-upcoming-october-investor-conferences-301394276.html
SOURCE Citius Pharmaceuticals, Inc.
资料来源：花旗制药公司(Citius PharmPharmticals，Inc.)
https://rt.prnewswire.com/rt.gif?NewsItemId=NE31297&Transmission_Id=202110061040PR_NEWS_USPR_____NE31297&DateId=20211006
Https://rt.prnewswire.com/rt.gif?NewsItemId=NE31297&Transmission_Id=202110061040PR_NEWS_USPR_NE31297&DateId=20211006
COMTEX_394670182/1005/2021-10-06T10:40:32
COMETX_394670182/1005/2021-10-06T10：40：32
译文内容由第三方软件翻译。